Apr 30
Aravax Appoints Dr Paul Laidler as VP Pharmaceutical Development
1 May 2024, Melbourne, Australia: Aravax, a clinical-stage biotechnology company developing next- generation immunotherapies which are...
top of page
Developing safe, convenient, disease-modifying treatments for food allergies.
.jpg)
News
bottom of page